MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.…
MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026
MediWound (NASDAQ: MDWD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 121 employees.
The shares were at 13.59 USD on 20 November 2026, down 25.4% over 52 weeks. Its 52-week range is 11.80 USD to 19.70 USD: the price is 31.0% below the high and 15.2% above the low.
Its market capitalisation is 195.56M USD.
MediWound reports return on equity of -54.7%, an operating margin of -337.6% and revenue down 34.2% year over year.
It holds more cash than debt, a net cash position of 19.55M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 29.67 USD is 118.3% above the current price. The next earnings report is expected on 4 March 2027.